The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Recent Advances in Neuroblastoma
Open accessAbstract
Neuroblastoma, an embryonal cancer of the autonomic nervous system, is the most common cancer diagnosed during the first year of life. Although neuroblastoma accounts for disproportionately high morbidity and mortality among childhood cancers, it has one of the highest rates of spontaneous and complete regression. The author discusses recent advances in our understanding of neuroblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel, V, Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1466 · Cited by 2,294
Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Self-citationAssociation of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Cohn, S. L., Pearson, A. D. J., London, W. B., Monclair, T., Ambros, P. F., Brodeur, G. M., Faldum, A., Hero, B., Iehara, T., Machin, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6785 · Cited by 1,910
Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898
Identification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407
Self-citationSchwab, M., Alitalo, K., Klempnauer, K.-H., Varmus, H. E., Bishop, J. M., Gilbert, F., Brodeur, G., Goldstein, M., & Trent, J. (1983) · Nature · doi:10.1038/305245a0 · Cited by 1,407
Biedler, J. L., Helson, L., & Spengler, B. A. (1973) · PubMed · Cited by 1,295
The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
Monclair, T., Brodeur, G. M., Ambros, P. F., Brisse, H. J., Cecchetto, G., Holmes, K., Kaneko, M., London, W. B., Matthay, K. K., Nuchtern, J. G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6876 · Cited by 1,150
Oncogenic mutations of ALK kinase in neuroblastoma
Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., et al. (2008) · Nature · doi:10.1038/nature07399 · Cited by 916
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 894
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893
Targeted expression of MYCN causes neuroblastoma in transgenic mice
Weiss, W. A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.11.2985 · Cited by 870
Shimada, H., Chatten, J., Newton, W. A., Sachs, N., Hamoudi, A. B., Chiba, T., Marsden, H. B., & Misugi, K. (1984) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/73.2.405 · Cited by 862
Nakagawara, A., Arima-Nakagawara, M., Scavarda, N. J., Azar, C. G., Cantor, A. B., & Brodeur, G. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199303253281205 · Cited by 694
Thiele, C. J., Reynolds, C. P., & Israel, M. A. (1985) · Nature · doi:10.1038/313404a0 · Cited by 642
Brodeur, G. M., Seeger, R. C., Barrett, A., Berthold, F., Castleberry, R. P., D'Angio, G., De Bernardi, B., Evans, A. E., Favrot, M., & Freeman, A. I. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1874 · Cited by 608
The neurocristopathiesA unifying concept of disease arising in neural crest maldevelopment
BOLANDE, R. (1974) · Human Pathology · doi:10.1016/s0046-8177(74)80021-3 · Cited by 595
London, W. B., Castleberry, R. P., Matthay, K. K., Look, A. T., Seeger, R. C., Shimada, H., Thorner, P., Brodeur, G., Maris, J. M., Reynolds, C. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.571 · Cited by 589
Self-citationChromosome 1p and 11q Deletions and Outcome in Neuroblastoma
Attiyeh, E. F., London, W. B., Mossé, Y. P., Wang, Q., Winter, C., Khazi, D., McGrady, P. W., Seeger, R. C., Look, A. T., Shimada, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052399 · Cited by 580
Self-citationLook, A. T., Hayes, F. A., Nitschke, R., McWilliams, N. B., & Green, A. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198407263110405 · Cited by 491
Neuroblastoma Screening at One Year of Age
Schilling, F. H., Spix, C., Berthold, F., Erttmann, R., Fehse, N., Hero, B., Klein, G., Sander, J., Schwarz, K., Treuner, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012277 · Cited by 464
Expression and function of TRK-B and BDNF in human neuroblastomas.
Nakagawara, A., Azar, C. G., Scavarda, N. J., & Brodeur, G. M. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.759 · Cited by 423
Cheung, N. K., Lazarus, H., Miraldi, F. D., Abramowsky, C. R., Kallick, S., Saarinen, U. M., Spitzer, T., Strandjord, S. E., Coccia, P. F., & Berger, N. A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.9.1430 · Cited by 417
Berthold, F., Boos, J., Burdach, S., Erttmann, R., Henze, G., Hermann, J., Klingebiel, T., Kremens, B., Schilling, F. H., Schrappe, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70291-6 · Cited by 402
SPECIAL PATTERN OF WIDESPREAD NEUROBLASTOMA WITH A FAVOURABLE PROGNOSIS
D'Angio, G., Evans, A., & Koop, C. E. (1971) · The Lancet · doi:10.1016/s0140-6736(71)91606-0 · Cited by 401
Gm, B., Pritchard, J., Berthold, F., Nl, C., Castel, V., Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1994) · PubMed · Cited by 392
(1982) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/68.4.589 · Cited by 376
Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients.
Schulz, G., Cheresh, D. A., Varki, N. M., Yu, A. L.-T., Staffileno, L. K., & Reisfeld, R. A. (1984) · PubMed · Cited by 368
Germline Mutations of the Paired–Like Homeobox 2B (PHOX2B) Gene in Neuroblastoma
Trochet, D., Bourdeaut, F., Janoueix-Lerosey, I., Deville, A., de Pontual, L., Schleiermacher, G., Coze, C., Philip, N., Frébourg, T., Munnich, A., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/383253 · Cited by 358
Copy number variation at 1q21.1 associated with neuroblastoma
Diskin, S. J., Hou, C., Glessner, J. T., Attiyeh, E. F., Laudenslager, M., Bosse, K., Cole, K., Mossé, Y. P., Wood, A., Lynch, J. E., et al. (2009) · Nature · doi:10.1038/nature08035 · Cited by 354
Self-citationOverall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma
Janoueix-Lerosey, I., Schleiermacher, G., Michels, E., Mosseri, V., Ribeiro, A., Lequin, D., Vermeulen, J., Couturier, J., Peuchmaur, M., Valent, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0630 · Cited by 349
Mutation and cancer: neuroblastoma and pheochromocytoma.
Knudson, A. G., & Strong, L. C. (1972) · PubMed · Cited by 341
Chromosome 6p22 Locus Associated with Clinically Aggressive Neuroblastoma
Maris, J. M., Mosse, Y. P., Bradfield, J. P., Hou, C., Monni, S., Scott, R. H., Asgharzadeh, S., Attiyeh, E. F., Diskin, S. J., Laudenslager, M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708698 · Cited by 319
Self-citationHero, B., Simon, T., Spitz, R., Ernestus, K., Gnekow, A. K., Scheel-Walter, H.-G., Schwabe, D., Schilling, F. H., Benz-Bohm, G., & Berthold, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3349 · Cited by 311
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma
Capasso, M., Devoto, M., Hou, C., Asgharzadeh, S., Glessner, J. T., Attiyeh, E. F., Mosse, Y. P., Kim, C., Diskin, S. J., Cole, K. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.374 · Cited by 305
Self-citationThe Transformation of a Malignant Paravertebral Sympathicoblastoma into a Benign Ganglioneuroma.
Cushing, H., & Sb, W. (1927) · PubMed Central · Cited by 303
Oberthuer, A., Berthold, F., Warnat, P., Hero, B., Kahlert, Y., Spitz, R., Ernestus, K., König, R., Haas, S., Eils, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1879 · Cited by 291
Germline PHOX2B Mutation in Hereditary Neuroblastoma
Mosse, Y. P., Laudenslager, M., Khazi, D., Carlisle, A. J., Winter, C. L., Rappaport, E., & Maris, J. M. (2004) · The American Journal of Human Genetics · doi:10.1086/424530 · Cited by 284
Self-citationMatthay, K. K., Yanik, G., Messina, J., Quach, A., Huberty, J., Cheng, S.-C., Veatch, J., Goldsby, R., Brophy, P., Kersun, L. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3484 · Cited by 264
Self-citationPark, S. M., Lim, M. K., Shin, S. A., & Yun, Y. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0243 · Cited by 263
Shusterman, S., London, W. B., Gillies, S. D., Hank, J. A., Voss, S. D., Seeger, R. C., Reynolds, C. P., Kimball, J., Albertini, M. R., Wagner, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.8861 · Cited by 248
Self-citationMujoo, K., Cheresh, D. A., Yang, H. M., & Reisfeld, R. A. (1987) · PubMed · Cited by 246
Asgharzadeh, S., Pique-Regi, R., Sposto, R., Wang, H., Yang, Y., Shimada, H., Matthay, K., Buckley, J., Ortega, A., & Seeger, R. C. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj330 · Cited by 237
A population-based study of the usefulness of screening for neuroblastoma
Woods, W. G., Tuchman, M., Robison, L. L., Bernstein, M., Leclerc, J.-M., Brisson, L. C., Brossard, J., Hill, G., Shuster, J., Luepker, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)06020-5 · Cited by 231
Maris, J. M., Morton, C. L., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., Keir, S. T., Reynolds, C. P., Kang, M. H., Wu, J., et al. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22430 · Cited by 226
Self-citationMatthay, K. K., DeSantes, K., Hasegawa, B., Huberty, J., Hattner, R. S., Ablin, A., Reynolds, C. P., Seeger, R. C., Weinberg, V. K., & Price, D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.229 · Cited by 222
George, R. E., Li, S., Medeiros-Nancarrow, C., Neuberg, D., Marcus, K., Shamberger, R. C., Pulsipher, M., Grupp, S. A., & Diller, L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6986 · Cited by 205
Matthay, K. K., Tan, J. C., Villablanca, J. G., Yanik, G. A., Veatch, J., Franc, B., Twomey, E., Horn, B., Reynolds, C. P., Groshen, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6400 · Cited by 197
Self-citationPhase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.
Garaventa, A., Luksch, R., Piccolo, M. S. L., Cavadini, E., Montaldo, P. G., Pizzitola, M. R., Boni, L., Ponzoni, M., DeCensi, A., Bernardi, B. D., et al. (2003) · PubMed · Cited by 188
Pritchard, J., Cotterill, S. J., Germond, S. M., Imeson, J., de Kraker, J., & Jones, D. R. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20219 · Cited by 183
Wei, J. S., Greer, B. T., Westermann, F., Steinberg, S. M., Son, C.-G., Chen, Q.-R., Whiteford, C. C., Bilke, S., Krasnoselsky, A. L., Cenacchi, N., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0695 · Cited by 182
Osenga, K. L., Hank, J. A., Albertini, M. R., Gan, J., Sternberg, A. G., Eickhoff, J., Seeger, R. C., Matthay, K. K., Reynolds, C. P., Twist, C., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2000 · Cited by 180
Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.
Kushner, B. H., LaQuaglia, M. P., Bonilla, M. A., Lindsley, K., Rosenfield, N., Yeh, S., Eddy, J., Gerald, W. L., Heller, G., & Cheung, N. K. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2607 · Cited by 174
Inhibition of ALK Signaling for Cancer Therapy
Mossé, Y. P., Wood, A., & Maris, J. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2762 · Cited by 172
Self-citationBarker, E., Mueller, B. M., Handgretinger, R., Herter, M., Yu, A. L.-T., & Reisfeld, R. A. (1991) · PubMed · Cited by 164
Ohira, M., Oba, S., Nakamura, Y., Isogai, E., Kaneko, S., Nakagawa, A., Hirata, T., Kubo, H., Goto, T., Yamada, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.019 · Cited by 155
Hoehner, J. C., Gestblom, C., Hedborg, F., Sandstedt, B., Olsen, L., & Påhlman, S. (1996) · PubMed · Cited by 153
Hank, J. A., Robinson, R. R., Surfus, J. E., Mueller, B. M., Reisfeld, R. A., Cheung, N. K., & Sondel, P. M. (1990) · PubMed · Cited by 151
Simon, T., Hero, B., Faldum, A., Handgretinger, R., Schrappe, M., NIETHAMMER, D., & Berthold, F. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.143 · Cited by 141
London, W. B., Frantz, C. N., Campbell, L., Seeger, R. C., Brumback, B., Cohn, S. L., Matthay, K. K., Castleberry, R. P., & Diller, L. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5016 · Cited by 136
3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.
Cheung, N. V., Kushner, B. H., Yeh, S. D. J., & Larson, S. M. (1998) · International Journal of Oncology · doi:10.3892/ijo.12.6.1299 · Cited by 122
Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma
DuBois, S. G., & Matthay, K. K. (2008) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2008.05.002 · Cited by 117
Schmidt, M. C., Simon, T., Hero, B., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.013 · Cited by 95
Katzenstein, H. M., Cohn, S. L., Shore, R. M., Bardo, D. M. E., Haut, P. R., Olszewski, M., Schmoldt, J., Liu, D., RADEMAKER, A. W., & Kletzel, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.144 · Cited by 95
Garaventa, A., Luksch, R., Biasotti, S., Severi, G., Pizzitola, M. R., Viscardi, E., Prete, A., Mastrangelo, S., Podda, M. G., Haupt, R., et al. (2003) · Cancer · doi:10.1002/cncr.11797 · Cited by 90
Spitz, R., Oberthuer, A., Zapatka, M., Brors, B., Hero, B., Ernestus, K., Oestreich, J., Fischer, M., Simon, T., & Berthold, F. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20376 · Cited by 80
A mechanism for neutrophil-mediated lysis of human neuroblastoma cells.
Barker, E., & Reisfeld, R. A. (1993) · PubMed · Cited by 72
Boyd, M., Mairs, R. J., Keith, W. N., Ross, S. C., Welsh, P. C., Akabani, G., Owens, J., Vaidyanathan, G., Carruthers, R., Dorrens, J., et al. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.578 · Cited by 55
Stage 4S neuroblastoma: what makes it special?
Matthay, K. K. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2003 · Cited by 37
Cited by
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Matthay, K. K., Maris, J. M., Schleiermacher, G., Nakagawara, A., Mackall, C. L., Diller, L., & Weiss, W. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.78 · Cited by 1,419
Self-citationGlutamine and cancer: cell biology, physiology, and clinical opportunities
Hensley, C. T., Wasti, A. T., & DeBerardinis, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69600 · Cited by 1,262
“MYCN amplification occurs in 20%–25% of neuroblastomas and is correlated with poor outcome (31).”
The genetic landscape of high-risk neuroblastoma
Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., Carter, S. L., Cibulskis, K., Hanna, M., Kiezun, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2529 · Cited by 1,186
Self-citationAdvances in Risk Classification and Treatment Strategies for Neuroblastoma
Pinto, N. R., Applebaum, M. A., Volchenboum, S. L., Matthay, K. K., London, W. B., Ambros, P. F., Nakagawara, A., Berthold, F., Schleiermacher, G., Park, J. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4648 · Cited by 911
Metadata
- Authors
- Maris, J. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-06-10
- Volume
- 362
- Issue
- 23
- Pages
- 2202-2211
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2130925781
- Cited by
- 1,983
- References
- 71
- FWCI
- 48.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.